Ruxolitinib

Ruxolitinib

Definition

An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.

Also known as (3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile, INCB 018424, INCB-018424, INCB-18424, INCB18424, Oral JAK Inhibitor INCB18424, RUXOLITINIB — per NCIT

Also identified as

Indications

Disease Relation Source
Acquired polycythemia vera may treat MEDRT · Public domain (U.S. Government work)
Primary myelofibrosis may treat MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ Side effect / interaction Source
Bone marrow may treat a disease of this organ DERIVED · CC BY 4.0

1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.